Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.
This test employs a combination of tumour-agnostic next-generation sequencing (NGS) and personalised tumour-informed droplet digital PCR (dd-PCR) assay.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A small number of tumour cells might remain in the patient’s body after initial anti-cancer treatments, posing a risk of relapse.
Conventional genomic and imaging methods often fail to identify this minimal residual disease. The system aims to fill this gap by providing ultra-sensitive detection, as well as monitoring at the molecular level. This enables the early intervention of oncologists and potentially preventing disease progression, the company noted.
DCG global strategy and medical affairs senior director Dr Darshana Patil said: “Target-MRD reflects DCG’s commitment to safe, reliable and accurate technologies. It is the next-generation test that has the potential not only to detect recurrence earlier but to adapt itself to each patient’s individual requirements and helps to personalise cancer management decisions.
“With its ability to sensitively detect minimal residual disease, Target-MRD empowers clinicians with the information they need to make timely, data-driven decisions, improving patient outcomes and ultimately transforming the way cancer is managed.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOncology research and applications company DCG is at the forefront of developing non-invasive technologies for identifying, treating, and managing cancer.
The company provides services to individuals suffering from cancer across India, the Gulf Cooperation Council (GCC), the UK, the EU, and the US.
In January 2023, the US Food and Drug Administration (FDA) granted breakthrough device designation to the company’s TriNetra-Glio blood test, which is intended to assist in the diagnosis of inaccessible brain tumours.
